5 years later: irisin detection still an issue

Cooke, Alexandra B.; Gomez, Yessica-Haydee; Daskalopoulou, Stella S.

doi:10.1530/eje-17-0572

Cited by 14 publications

(13 citation statements)

References 12 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonetheless, the significant difference in irisin levels between ATPIII(+) and overweight PCOS patients and their corresponding controls suggested that the irisin level indeed has a tendency to increase in PCOS patients. On the other hand, it has been shown that the commercially available assay kits for irisin have high coefficients of variation 60 . Therefore, further studies with different assay techniques, and a larger and better defined patient population are needed to verify the present findings.…”

Section: Discussionmentioning

confidence: 99%

The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients

Chang

Huang

Hsu

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, oligo- or anovulation, and/or polycystic ovary. It frequently presents with dyslipidemia and insulin resistance. Recent studies have shown that the white adipose tissue-derived asprosin is elevated in humans with insulin resistance. Because many PCOS patients have a propensity to develop dyslipidemia and/or insulin resistance, asprosin metabolism could be dysregulated in PCOS patients. Accordingly, we investigated serum levels of asprosin, irisin, GIP, androgens, LH, glucose, insulin, and lipids as well as HOMA-IR, QUICKI and ISI Matsuda in a cohort of 444 PCOS patients and 156 controls. Patients were stratified based on metabolic syndrome risk factors (ATPIII [+] and [−] groups), or BMI (overweight and lean groups). The irisin level was significantly correlated with body weight, SBP, DBP, Ferriman–Gallwey score, and levels of TSH, triglycerides, glucose and insulin in the overall population, and was elevated in ATPIII(+) and overweight PCOS patients compared to corresponding controls. By contrast, asprosin levels in PCOS, ATPIII(+), or overweight patients were similar to those of corresponding controls. This finding indicated that the regulation of irisin, but not asprosin, metabolism is abnormal in PCOS patients, and this metabolic characteristic is distinctly different from that of diabetes patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients

Chang

Huang

Hsu

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…A recent meta-analysis found that irisin concentration increased by~15% immediately following an acute bout of exercise and identified fitness level as the single best predictorbeing fit was associated with a nearly two-fold increase in post-exercise irisin concentration, compared with being unfit [17]. Considerable uncertainty remains regarding the veracity of methods used for the dosage of serum irisin [18]. Although Jedrychowski et al [19] have indisputably detected and quantified circulating human irisin by tandem mass spectrome-try, assessing that its concentration is~3.6 ng/mL (~300 pmol/L) in sedentary humans and 4.3 ng/mL (~358 pmol/L) in individuals undergoing aerobic interval training, currently available ELISA assays for quantifying circulating irisin levels still lack of quality and accuracy, and the measured values are very dissimilar between the different assays [18,20].…”

Section: Glp-1 and Irisin Synthesis Secretion And Mechanism Of Actimentioning

confidence: 99%

“…Considerable uncertainty remains regarding the veracity of methods used for the dosage of serum irisin [18]. Although Jedrychowski et al [19] have indisputably detected and quantified circulating human irisin by tandem mass spectrome-try, assessing that its concentration is~3.6 ng/mL (~300 pmol/L) in sedentary humans and 4.3 ng/mL (~358 pmol/L) in individuals undergoing aerobic interval training, currently available ELISA assays for quantifying circulating irisin levels still lack of quality and accuracy, and the measured values are very dissimilar between the different assays [18,20]. This may partially explain the discrepant data found by different research groups, especially in the setting of serum irisin measurements.…”

Section: Glp-1 and Irisin Synthesis Secretion And Mechanism Of Actimentioning

confidence: 99%

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity

et al. 2021

View full text Add to dashboard Cite

Incretins are gut hormones that potentiate glucose-stimulated insulin secretion (GSIS) after meals. Glucagon-like peptide-1 (GLP-1) is the most investigated incretin hormone, synthesized mainly by L cells in the lower gut tract. GLP-1 promotes β-cell function and survival and exerts beneficial effects in different organs and tissues. Irisin, a myokine released in response to a high-fat diet and exercise, enhances GSIS. Similar to GLP-1, irisin augments insulin biosynthesis and promotes accrual of β-cell functional mass. In addition, irisin and GLP-1 share comparable pleiotropic effects and activate similar intracellular pathways. The insulinotropic and extra-pancreatic effects of GLP-1 are reduced in type 2 diabetes (T2D) patients but preserved at pharmacological doses. GLP-1 receptor agonists (GLP-1RAs) are therefore among the most widely used antidiabetes drugs, also considered for their cardiovascular benefits and ability to promote weight loss. Irisin levels are lower in T2D patients, and in diabetic and/or obese animal models irisin administration improves glycemic control and promotes weight loss. Interestingly, recent evidence suggests that both GLP-1 and irisin are also synthesized within the pancreatic islets, in α- and β-cells, respectively. This review aims to describe the similarities between GLP-1 and irisin and to propose a new potential axis–involving the gut, muscle, and endocrine pancreas that controls energy homeostasis.

show abstract

“…It seems that diverse confounders may have affected the results of different clinical studies. 9 Ethnicity emerged as a determinant in the association between adiposity, glucose tolerance status and irisin. 1 Because irisin is still an appealing molecule from a pathophysiological point of view and a therapeutic target for obesity and metabolic disease, so far data concerning the Chinese population was limited.…”

Section: Introductionmentioning

confidence: 99%

<p>Association of Circulating Irisin Levels with Adiposity and Glucose Metabolic Profiles in a Middle-Aged Chinese Population: A Cross-Sectional Study</p>

Zhang

Zhao

et al. 2020

DMSO

View full text Add to dashboard Cite

Objective The myokine irisin has been proposed to affect obesity and metabolism disorders. However, data about the association of irisin with obesity and glucose metabolic status in humans remains controversial, and limited data are available concerning the Chinese population. This study aimed to evaluate the association between serum irisin concentrations and obesity, as well as glucose metabolic and cardiovascular factors in the middle-aged physical activity-matched Chinese Han race population. Methods A total of 740 participants were included in this cross-sectional study, who were divided into a normal weight (NW) group, overweight/obese (OB) group, normal weight type 2 diabetes (DM-NW) group and overweight/obese diabetes (DM-OB) group, and physical activity was evaluated and matched for the four groups. Circulating irisin levels were analyzed and compared among the groups with different adiposity and glucose status. Linear regression analysis was performed to test the relationship between serum irisin and adiposity indices, glucose metabolic and other cardiovascular risk factors. Results Circulating irisin levels were significantly correlated with higher levels of direct and indirect adiposity markers, including BMI, waist circumference and fat mass, and other cardiovascular risk factors, such as plasma triglyceride and low-density lipoprotein cholesterol level (p < 0.01). Diabetes patients had lower irisin levels compared to non-diabetes participants, in either normal weight and obese group, resulting in a correlation of irisin with HbA1c, HOMA-IR and HOMA-IS (p < 0.01). Linear regression analysis demonstrated that irisin serum concentrations were independently associated with sex, BMI, HbA1c, HOMA-IR and HOMA-IS (R 2 = 0.465). Conclusion These data indicated that circulating irisin was affected by adiposity and glucose metabolism condition in the middle-aged Chinese population. The increase of irisin under conditions of obesity may indicate its physiological function to improve glucose tolerance which is often impaired in obese subjects, but this compensatory secretion of irisin seems likely to be progressing to a secretion failure once diabetes developed.

show abstract

5 years later: irisin detection still an issue

Cited by 14 publications

References 12 publications

The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients

The serum level of irisin, but not asprosin, is abnormal in polycystic ovary syndrome patients

Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity

<p>Association of Circulating Irisin Levels with Adiposity and Glucose Metabolic Profiles in a Middle-Aged Chinese Population: A Cross-Sectional Study</p>

Contact Info

Product

Resources

About